A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

NCT04987489 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease
Thalassemia

Interventions

DRUG: Etavopivat tablets

Sponsor

Forma Therapeutics, Inc.